Revance Therapeutics (NASDAQ:RVNC – Get Rating) had its price objective upped by investment analysts at HC Wainwright from $29.00 to $42.00 in a note issued to investors on Thursday, The Fly reports. The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. HC Wainwright's target price would suggest a potential upside of 26.77% from the company's previous close.
Other equities research analysts have also recently issued reports about the stock. Guggenheim lifted their price objective on shares of Revance Therapeutics to $36.00 in a research report on Tuesday, November 15th. Needham & Company LLC lifted their price objective on shares of Revance Therapeutics from $35.00 to $38.00 and gave the stock a "buy" rating in a research report on Tuesday, January 10th. Morgan Stanley lifted their price objective on shares of Revance Therapeutics from $25.00 to $26.00 and gave the stock an "equal weight" rating in a research report on Tuesday. StockNews.com cut shares of Revance Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, October 13th. Finally, Barclays lifted their price objective on shares of Revance Therapeutics from $35.00 to $37.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $39.60.
Get Revance Therapeutics alerts:Revance Therapeutics Stock Performance
Shares of RVNC stock opened at $33.13 on Thursday. The company has a quick ratio of 5.33, a current ratio of 5.56 and a debt-to-equity ratio of 2.60. Revance Therapeutics has a 52 week low of $11.27 and a 52 week high of $34.55. The stock has a market capitalization of $2.73 billion, a PE ratio of -8.45 and a beta of 0.57. The firm has a 50 day moving average of $23.53 and a two-hundred day moving average of $22.64.
Revance Therapeutics (NASDAQ:RVNC – Get Rating) last issued its quarterly earnings results on Tuesday, November 8th. The biopharmaceutical company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.32). Revance Therapeutics had a negative net margin of 251.92% and a negative return on equity of 461.54%. The business had revenue of $29.02 million during the quarter, compared to analysts' expectations of $28.76 million. On average, research analysts predict that Revance Therapeutics will post -4.32 EPS for the current fiscal year.Insider Buying and Selling at Revance Therapeutics
In other Revance Therapeutics news, CFO Tobin Schilke sold 1,000 shares of Revance Therapeutics stock in a transaction on Friday, January 20th. The shares were sold at an average price of $31.00, for a total value of $31,000.00. Following the transaction, the chief financial officer now directly owns 57,877 shares in the company, valued at $1,794,187. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 5.10% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Mark Sheptoff Financial Planning LLC acquired a new position in Revance Therapeutics in the third quarter valued at $54,000. Advisor Group Holdings Inc. increased its stake in shares of Revance Therapeutics by 60.6% during the first quarter. Advisor Group Holdings Inc. now owns 2,838 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 1,071 shares during the period. Princeton Global Asset Management LLC acquired a new position in shares of Revance Therapeutics during the third quarter worth about $68,000. Point72 Hong Kong Ltd acquired a new position in shares of Revance Therapeutics during the second quarter worth about $92,000. Finally, Quantbot Technologies LP acquired a new position in shares of Revance Therapeutics during the third quarter worth about $138,000. 82.68% of the stock is currently owned by institutional investors and hedge funds.
About Revance Therapeutics
(Get Rating)
Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.
Read More
- Get a free copy of the StockNews.com research report on Revance Therapeutics (RVNC)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.